Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Costs and Expenses:
General and administrative	$ 1,286,000	$ 1,044,000	$ 2,679,000	$ 2,199,000
Research and development	1,603,000	2,594,000	3,238,000	5,012,000
Total Operating Costs and Expenses	2,889,000	3,638,000	5,917,000	7,211,000
Loss from Operations	(2,889,000)	(3,638,000)	(5,917,000)	(7,211,000)
Other Income :
Interest income	6,000	80,000	44,000	125,000
Total Other Income	6,000	80,000	44,000	125,000
Net Loss	(2,883,000)	(3,558,000)	(5,873,000)	(7,086,000)
Net Loss Attributable to Non-controlling Interest	(16,000)	(27,000)	(42,000)	(43,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(2,867,000)	(3,531,000)	(5,831,000)	(7,043,000)
Net Loss Attributable to Common Stockholders	$ (3,322,000)	$ (3,709,000)	$ (6,752,000)	$ (7,680,000)
Net Loss Per Share - Basic and Dilutive	$ (0.18)	$ (0.23)	$ (0.38)	$ (0.48)
Weighted average number of shares outstanding during the period - Basic and Dilutive	18,405,884	16,465,314	17,748,688	16,063,283
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (63,000)	$ (61,000)	$ (125,000)	$ (122,000)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (392,000)	$ (117,000)	$ (796,000)	$ (515,000)